You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《外圍股市》美股期貨全面反覆回落0.2%-0.5% 道指期貨僅跌64點
美國經濟數據普遍勝預期,加上美國藥廠默克(MRK.US)研發新冠口服藥能使確診者住院和死亡率減半,美股上周五全面反彈,尤其是道指及標普分別由逾三個月及兩個月低位反彈1.4%及1.2%。亞太區股市今天普遍隨上周五美股反彈,尤其是印度、新加坡、澳洲及印尼股市彈1%-1.5%。然而,台股、日經跌1%及逾2%;港股長周末假後重開,在重磅股匯控(00005.HK)/建行(00939.HK)/友邦(01299.HK)/平安(02318.HK)/招行(03968.HK)/美團(03690.HK)/屢尋底阿里巴巴(09988.HK)、信義玻璃(00868.HK)及藥明生物(02269.HK)挫逾1.5%-8.5%領跌,曾低見23,908,現報24,011,急挫563點或2.3%。 美股期貨全面反覆回軟,道指期貨高低見34,293/33,996,現報34,103,回吐64點或0.2%;標普五百期貨高低見4,362/4,320,現報4,332,回落11點或不足0.3%;納指一百期貨高低見14,835/14,652,現報14,686,回落75點或0.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account